Tag: Petrovax

NPO Petrovax Pharm is the leader among Russian companies engaged in research, development and production of innovative medicines and vaccines.
Founded in 1996 by a group of Russian scientists, the company aims to create, produce and promote original medicines across the national health care system.
Petrovax Pharm’s pharmaceutical production and warehousing complex (Podolsk District, Moscow Region) was opened in 2008 and is now one of the most advanced high-tech biopharmaceutical facilities in Russia.
It manufactures substances and liquid, semi-solid and solid dosage forms in disposable syringes, ampoules, vials and plastic containers. The production capacity is over 160 m doses of immunobiological medicines per year.
The facility includes a production and warehousing block, laboratories, a power block, a water treatment block, and an office and amenities building.
The complex currently comprises two production lines manufacturing Grippol® Plus and Prevenar® 13 vaccines in pre-filled syringes, along with Polyoxidonium® and Longidaze® in ampoules and vials. Construction of the third production line for substances, solid and semi-solid formulations is now in progress and is due to come on-stream in 2017. As the next step, the company plans to ramp up its production capacity to a total of four lines, expand its warehouse space, and add another office building.

Product Quality team currently has more than 80 professionals working to ensure impeccable quality for NPO Petrovax Pharm medicines across all production stages – from taking samples of starting materials to end product quality check. The production is fully compliant with the Russian and international GMP and ISO:9001 standards. The company is the only producer of immunobiological medicines in Russia holding GMP certificates issued by government regulators from the EU (Slovakia), Ukraine and Iran. The company operates its own warehouse to ensure proper storage of produced pharmaceuticals.
Petrovax Pharm has a set of well-established pre-production practices in place both for its vaccines and other medicines. It also carries out annual engineering audits and a full set of certification and validation procedures (certification of engineering systems and clean rooms, validation of aseptic filling and water treatment systems, preparation and packaging processes).

Petrovax launches the automation of drug registration business processes

Eureka BPO announced the launch of pilot operation of PHARDO system for LLC NPO Petrovax Pharm, a leading Russian developer and producer of innovative medicines and vaccines. The project allowed to au...

British-Russian consortium hopes to buy 25% of Serbia’s Galenika

A British-Russian consortium said they are close to an agreement for the purchase of 25% of Serbian majority state-owned drug maker Galenika, despite the government's recent announcement that the ...

IDF loan will enable Petrovax Pharm to increase production of substances and finished drugs

"The Advisory Committee of the Industrial Development Fund approved the first projects in 2017. Out of total 1.3 billion rubles for the implementation of the projects, 600 million rubles have to be co...

Petrovax Pharm is expanding production capacities

NPO Petrovax Pharm will increase the manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms (tablets and suppositories) of original local pharmaceuticals. It is planned to i...

Production of cardiovascular medications will be localized in Russia

NPO Petrovax Pharm and Boehringer Ingelheim continue their work to localise full-cycle production of biotechnological medicines to treat infarctions and cerebrovascular accidents. The project aiming ...